89 related articles for article (PubMed ID: 27662548)
1. In-utero exposure to nelfinavir-ethyl methyl sulfone.
Hleyhel M; Goujon S; Sibiude J; Blanche S; Warszawski J;
AIDS; 2016 Nov; 30(17):2729-2730. PubMed ID: 27662548
[TBL] [Abstract][Full Text] [Related]
2. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
3. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
4. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
5. Changes are recommended in use of nelfinavir.
Wilcox RD
HIV Clin; 2008; 20(1):1, 4. PubMed ID: 18578034
[No Abstract] [Full Text] [Related]
6. Risk of cancer in children exposed to didanosine in utero.
Hleyhel M; Goujon S; Delteil C; Vasiljevic A; Luzi S; Stephan JL; Reliquet V; Jannier S; Tubiana R; Dollfus C; Faye A; Mandelbrot L; Clavel J; Warszawski J; Blanche S;
AIDS; 2016 May; 30(8):1245-56. PubMed ID: 26854809
[TBL] [Abstract][Full Text] [Related]
7. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
Gerber C; Toelle HG
Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
[TBL] [Abstract][Full Text] [Related]
8. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
Gocke E; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
[TBL] [Abstract][Full Text] [Related]
9. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?
Boettiger DC; Sabin CA; Grulich A; Ryom L; Bonnet F; Reiss P; Monforte Ad; Kirk O; Phillips A; Bower M; Fätkenheuer G; Lundgren JD; Law M;
AIDS; 2016 Jun; 30(10):1629-37. PubMed ID: 26854812
[TBL] [Abstract][Full Text] [Related]
10. The Viracept-EMS case: impact and outlook.
Walker VE; Casciano DA; Tweats DJ
Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
12. In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana.
Powis KM; Smeaton L; Hughes MD; Tumbare EA; Souda S; Jao J; Wirth KE; Makhema J; Lockman S; Fawzi W; Essex M; Shapiro RL
AIDS; 2016 Jan; 30(2):211-20. PubMed ID: 26684818
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
[TBL] [Abstract][Full Text] [Related]
14. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.
Williams PL; Crain MJ; Yildirim C; Hazra R; Van Dyke RB; Rich K; Read JS; Stuard E; Rathore M; Mendez HA; Watts DH;
JAMA Pediatr; 2015 Jan; 169(1):48-55. PubMed ID: 25383770
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
[TBL] [Abstract][Full Text] [Related]
16. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
[TBL] [Abstract][Full Text] [Related]
17. The safety of sumatriptan and naratriptan in pregnancy: what have we learned?
Cunnington M; Ephross S; Churchill P
Headache; 2009; 49(10):1414-22. PubMed ID: 19804390
[TBL] [Abstract][Full Text] [Related]
18. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Scherpbier HJ; Bekker V; van Leth F; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2006 Mar; 117(3):e528-36. PubMed ID: 16481448
[TBL] [Abstract][Full Text] [Related]
19. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
[TBL] [Abstract][Full Text] [Related]
20. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
Gocke E; Bürgin H; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
